FDCDDQ
RNAZ icon

Federation des caisses Desjardins du Quebec’s TransCode Therapeutics RNAZ Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-975
Closed -$10.5K – 2985
2025
Q3 		$10.5K Buy
+975
New +$10.2K ﹤0.01% 2247

Other funds holding RNAZ

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's RNAZ Position: Q4 2025 in Review

Federation des caisses Desjardins du Quebec sold out of TransCode Therapeutics (RNAZ) in Q4 2025, closing a stake of 975 shares — an estimated $10.5K sold.

Federation des caisses Desjardins du Quebec first reported a position in RNAZ in Q3 2025 and held it in 1 quarter. The position peaked at $10.5K in Q3 2025. 6 funds tracked by Wall St. Rank hold RNAZ as of Q4 2025.

  • Federation des caisses Desjardins du Quebec reported no remaining TransCode Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 975 TransCode Therapeutics shares in Q4 2025, an estimated $10.5K.
  • Federation des caisses Desjardins du Quebec first reported a position in TransCode Therapeutics in Q3 2025 and held it in 1 quarter.
  • Federation des caisses Desjardins du Quebec's TransCode Therapeutics position peaked at $10.5K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q4 2025.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2025, filed 12 Feb 2026.